Investors
Press Releases 2010
- 09/02/2010
IntelGenx Achieves Positive Bioequivalence Results for Erectile Dysfunction Film Product
- 08/30/2010
IntelGenx and RedHill Announce Definitive Agreement for Anti-Migraine Film Product
- 08/27/2010
IntelGenx Announces Closing of Private Placement
- 08/12/2010
IntelGenx Reports Second Quarter 2010 Results and Highlights Recent Developments
- 08/11/2010
IntelGenx Announces Additions to Board and Issuance of Stock Options
- 06/21/2010
IntelGenx Reports on Meeting With FDA
- 05/14/2010
IntelGenx Reports First Quarter 2010 Results and Highlights Recent Developments
- 05/14/2010
IntelGenx Announces the Adjournment of the 2010 Annual General Meeting of Shareholders
- 05/11/2010
IntelGenx Acquires Full Ownership of High Dose Bupropion (CPI-300)
- 05/04/2010
IntelGenx Announces Manufacturing Partnership and Ownership Position in Manufacturing Facility
- 04/21/2010
IntelGenx Announces Licensing of Anti-Migraine Film Product
- 04/07/2010
IntelGenx to Present at BioFinance 2010
- 03/31/2010
IntelGenx Reports Q4 and Full Year 2009 Financial Results and Summarizes Development Milestones Achieved
- 03/10/2010
IntelGenx Granted Bupropion Patent
- 03/04/2010
IntelGenx and Cannasat Announce Letter of Intent for Relivar License
- 02/08/2010
IntelGenx Receives FDA Complete Response Letter CPI-300
- 01/25/2010
IntelGenx Enters Strategic Manufacturing Partnership for VersaFilm Technology
- 01/22/2010
IntelGenx Grants Options to IR Firm
- 01/21/2010
IntelGenx Receives Notice of Allowance for Bupropion Patent
- 01/11/2010
IntelGenx Announces Manufacturing Site Change for CPI-300